

Table of Contents

1	Introduction	1
2	Classification of Myelin Disorders	4
3	White Matter and Myelin	9
3.1	Introduction	9
3.2	Morphology of Myelin	9
3.3	Myelinogenesis	13
3.4	Progress of Myelination in the Brain	14
3.5	Factors that Influence Myelination	15
3.6	Remyelination	15
3.7	Biochemistry of Adult Myelin and White Matter	15
3.8	Biochemical Composition of the Nonmyelin Portion of White Matter	18
3.9	Compositional Changes in the Developing Brain	18
3.10	Myelin Turnover	19
3.11	Aging of Myelin	20
3.12	Function of Myelin	20
3.13	Myelin Disorders and Demyelination	21
4	Basic Principles of Magnetic Resonance Imaging and Its Application in Myelin Disorders	22
4.1	General Principles	22
4.2	Inversion Recovery	22
4.3	Spin Echoes	23
4.4	Gradient (Recalled) Echoes	23
4.5	Short TI Inversion Recovery	23
4.6	Gadolinium DTPA	24
5	Myelination and Retarded Myelination	26
5.1	Myelination in Magnetic Resonance Imaging	26
5.2	Pulse Sequences and Myelination	27
5.3	Retarded Myelination, Hypomyelination, and Arrest of Myelination	28
5.4	Magnetic Resonance Imaging	30
6	Lysosomes and Lysosomal Disorders	66
7	Metachromatic Leukodystrophy	68
7.1	Clinical Features and Laboratory Investigations	68
7.2	Pathology	69
7.3	Chemical Pathology	69
7.4	Pathogenetic Considerations	70
7.5	Therapy	71
7.6	Case Presentation	72
7.7	Magnetic Resonance Imaging	76

8	Globoid Cell Leukodystrophy: Krabbe's Disease	77
8.1	Clinical Features and Laboratory Investigations	77
8.2	Pathology	77
8.3	Chemical Pathology	78
8.4	Pathogenetic Considerations	78
8.5	Therapy	79
8.6	Case Presentation	80
8.7	Magnetic Resonance Imaging	82
9	Wolman's Disease and Cholesterol Ester Storage Disease	83
9.1	Clinical Features and Laboratory Investigations	83
9.2	Pathology	83
9.3	Chemical Pathology	84
9.4	Pathogenetic Considerations	84
9.5	Therapy	84
9.6	Magnetic Resonance Imaging	84
10	Niemann-Pick Disease	85
10.1	Clinical Features and Laboratory Investigations	85
10.2	Pathology	86
10.3	Chemical Pathology	86
10.4	Pathogenetic Considerations	86
10.5	Therapy	87
10.6	Magnetic Resonance Imaging	87
11	GM₁ Gangliosidosis	88
11.1	Clinical Features and Laboratory Investigations	88
11.2	Pathology	88
11.3	Chemical Pathology	89
11.4	Pathogenetic Considerations	89
11.5	Therapy	90
11.6	Magnetic Resonance Imaging	90
12	GM₂ Gangliosidosis	91
12.1	Clinical Features and Laboratory Investigations	91
12.2	Pathology	92
12.3	Chemical Pathology	93
12.4	Pathogenetic Considerations	93
12.5	Therapy	94
12.6	Magnetic Resonance Imaging	94
13	Fucosidosis	95
13.1	Clinical Features and Laboratory Investigations	95
13.2	Neuropathology	95
13.3	Pathogenetic Considerations	95
13.4	Therapy	96
13.5	Magnetic Resonance Imaging	96
14	Peroxisomes and Peroxisomal Disorders	97
15	Zellweger Cerebrohepato renal Syndrome	99
15.1	Clinical Features and Laboratory Investigations	99
15.2	Pathology	99
15.3	Pathogenetic Considerations	100
15.4	Therapy	102
15.5	Magnetic Resonance Imaging	103

16 Adrenoleukodystrophy	104
16.1 Clinical Features and Laboratory Investigations	104
16.2 Pathology	105
16.3 Chemical Pathology	106
16.4 Pathogenetic Considerations	106
16.5 Therapy	107
16.6 Case Presentation	108
16.7 Magnetic Resonance Imaging	112
17 Refsum's Disease	113
17.1 Clinical Features and Laboratory Investigations	113
17.2 Pathology	114
17.3 Chemical Pathology	115
17.4 Pathogenetic Considerations	115
17.5 Therapy	116
17.6 Case Presentation	117
17.7 Magnetic Resonance Imaging	118
18 Hyperpipecolic Acidemia	119
18.1 Clinical Features and Laboratory Investigations	119
18.2 Pathology	119
18.3 Chemical Pathology	120
18.4 Pathogenetic Considerations	120
18.5 Therapy	120
18.6 Magnetic Resonance Imaging	120
19 Pseudo-Zellweger Syndrome	121
20 Pseudo-neonatal Adrenoleukodystrophy	122
21 Cerebrotendinous Xanthomatosis	123
21.1 Clinical Features and Laboratory Investigations	123
21.2 Pathology	123
21.3 Chemical Pathology	124
21.4 Pathogenetic Considerations	124
21.5 Therapy	124
21.6 Magnetic Resonance Imaging	125
22 Abetalipoproteinemia	126
22.1 Clinical Features and Laboratory Investigations	126
22.2 Neuropathological Examination	126
22.3 Pathogenetic Considerations	126
22.4 Therapy	127
22.5 Magnetic Resonance Imaging	127
23 Mitochondria and Mitochondrial Dysfunction	128
24 Mitochondrial Leukoencephalopathy	130
24.1 Clinical Features and Laboratory Investigations	130
24.2 Pathology	131
24.3 Pathogenetic Considerations	132
24.4 Therapy	132
24.5 Case Presentation	134
24.6 Magnetic Resonance Imaging	136

25 Canavan's Disease	137
25.1 Clinical Features and Laboratory Investigations	137
25.2 Pathology	137
25.3 Chemical Pathology	138
25.4 Pathogenetic Considerations	138
25.5 Therapy	139
25.6 Case Presentation	140
25.7 Magnetic Resonance Imaging	140
26 Disorders of Amino Acid and Organic Acid Metabolism	141
26.1 Clinical Syndromes	141
26.2 Case Presentation	144
26.3 Magnetic Resonance Imaging	147
27 GM₃ Gangliosidosis	148
27.1 Clinical Features and Laboratory Investigations	148
27.2 Pathology	148
27.3 Chemical Pathology	148
27.4 Pathogenetic Considerations	148
27.5 Therapy	148
27.6 Magnetic Resonance Imaging	148
28 Cockayne's Disease	149
28.1 Clinical Features and Laboratory Investigations	149
28.2 Neuropathology	150
28.3 Chemical Pathology	150
28.4 Pathogenetic Considerations	150
28.5 Therapy	151
28.6 Case Presentation	152
28.7 Magnetic Resonance Imaging	154
29 Pelizaeus-Merzbacher Disease	155
29.1 Clinical Features and Laboratory Investigations	155
29.2 Neuropathological Findings	155
29.3 Chemical Pathology	156
29.4 Pathogenetic Considerations	157
29.5 Therapy	157
29.6 Case Presentation	158
29.7 Magnetic Resonance Imaging	164
30 Alexander's Disease	165
30.1 Clinical Features and Laboratory Investigations	165
30.2 Neuropathology	165
30.3 Chemical Pathology	166
30.4 Pathogenetic Considerations	166
30.5 Therapy	167
30.6 Case Presentation	168
30.7 Magnetic Resonance Imaging	172
31 Congenital Muscular Dystrophy of the Fukuyama Type	173
31.1 Clinical Features and Laboratory Investigations	173
31.2 Pathology	173
31.3 Chemical Pathology	174
31.4 Pathogenetic Considerations and Classification	174
31.5 Treatment	175
31.6 Other Muscular Disorders with Associated White Matter Affection	175

31.7	Case Presentation	176
31.8	Magnetic Resonance Imaging	178
32	Multiple Sclerosis, Neuromyelitis Optica, Concentric Sclerosis, and Schilder's Diffuse Sclerosis	179
32.1	Clinical Features and Laboratory Investigations	179
32.2	Pathology	181
32.3	Chemical Pathology	183
32.4	Pathogenetic Considerations	183
32.5	Therapy	186
32.6	Case Presentation	188
32.7	Magnetic Resonance Imaging	198
33	Acute Disseminated Encephalomyelitis and Acute Hemorrhagic Encephalomyelitis	206
33.1	Clinical Symptoms and Laboratory Investigations	206
33.2	Pathology	207
33.3	Pathogenetic Considerations	207
33.4	Therapy	208
33.5	Case Presentation	210
33.6	Magnetic Resonance Imaging	214
34	Progressive Multifocal Leukoencephalitis	215
34.1	Clinical Features and Laboratory Investigations	215
34.2	Pathology	215
34.3	Pathogenetic Considerations	216
34.4	Therapy	217
34.5	Case Presentation	218
34.6	Magnetic Resonance Imaging	220
35	Subacute Sclerosing Panencephalitis	221
35.1	Clinical Features and Laboratory Investigations	221
35.2	Pathology	222
35.3	Pathogenetic Considerations	222
35.4	Therapy	223
35.5	Magnetic Resonance Imaging	224
36	Progressive Rubella Panencephalitis	225
36.1	Clinical Features and Laboratory Investigations	225
36.2	Pathology	225
36.3	Pathogenesis	225
36.4	Therapy	226
36.5	Magnetic Resonance Imaging	226
37	Acquired Immunodeficiency Syndrome	227
37.1	Clinical Features and Laboratory Investigations	227
37.2	Neuropathology	229
37.3	Pathogenetic Considerations	231
37.4	Therapy	232
37.5	Case Presentation	234
37.6	Magnetic Resonance Imaging	240
38	Creutzfeldt-Jakob Disease	241
38.1	Clinical Features and Laboratory Investigations	241
38.2	Pathology	241
38.3	Pathogenetic Considerations	242

38.4 Therapy 243

38.5 Magnetic Resonance Imaging 243

39 Other Infections of the Brain 244

39.1 Clinical Syndromes 244

39.2 Case Presentation 246

39.3 Magnetic Resonance Imaging 252

40 Central Pontine and Extrapontine Myelinolysis 253

40.1 Clinical Features and Laboratory Investigations 253

40.2 Pathology 254

40.3 Pathogenetic Considerations 254

40.4 Therapy 255

40.5 Case Presentation 258

40.6 Magnetic Resonance Imaging 262

41 Vitamin B₁₂ Deficiency 263

41.1 Clinical Features and Laboratory Investigations 263

41.2 Pathology 263

41.3 Pathogenetic Considerations 263

41.4 Therapy 264

41.5 Magnetic Resonance Imaging 264

42 Marchiafava-Bignami Syndrome 265

42.1 Clinical Symptoms and Laboratory Investigations 265

42.2 Pathology 265

42.3 Pathogenesis 266

42.4 Therapy 266

42.5 Case Presentation 267

42.6 Magnetic Resonance Imaging 267

43 Other Toxic and Metabolic Leukoencephalopathies 268

43.1 Endogenous and Exogenous Toxins 268

43.2 Case Presentation 270

43.3 Magnetic Resonance Imaging 272

44 Posthypoxic Leukoencephalopathy 273

44.1 Clinical Features and Laboratory Investigations 273

44.2 Pathology 273

44.3 Pathogenetic Considerations 273

44.4 Therapy 274

44.5 Case Presentation 276

44.6 Magnetic Resonance Imaging 282

45 Subcortical Arteriosclerotic Encephalopathy 283

45.1 Clinical Features and Laboratory Investigations 283

45.2 Pathology 283

45.3 Pathogenetic Considerations 284

45.4 Therapy 284

45.5 Case Presentation 286

45.6 Magnetic Resonance Imaging 292

46 Other Hypoxic-Ischemic White Matter Lesions 293

46.1 Clinical Syndromes 293

46.2 Case Presentation 296

46.3 Magnetic Resonance Imaging 302

47 Leukoencephalopathy after Chemotherapy and/or Radiotherapy 303
47.1 Clinical Features and Laboratory Investigations 303
47.2 Pathology 303
47.3 Pathogenetic Considerations 304
47.4 Therapy 305
47.5 Case Presentation 306
47.6 Magnetic Resonance Imaging 308

48 Hydrocephalus 309
48.1 Clinical Features and Laboratory Investigations 309
48.2 Pathology 310
48.3 Pathogenetic Considerations 311
48.4 Therapy and Complications 312
48.5 Case Presentation 314
48.6 Magnetic Resonance Imaging 318

**49 Wallerian Degeneration and Demyelination Secondary to Neuronal
and Axonal Degeneration 319**
49.1 Introduction 319
49.2 Pathology 319
49.3 Chemical Pathology 320
49.4 Discussion 320
49.5 Case Presentation 322
49.6 Magnetic Resonance Imaging 326

50 Pattern Recognition in Magnetic Resonance Imaging of Myelin Disorders 327
50.1 Levels of Pattern Recognition 327
50.2 Examples of Pattern Recognition 330
50.3 Case Presentation 334

**51 Magnetic Resonance Spectroscopy, Basic Principles, and Application
in Myelin Disorders 344**
51.1 General Principles 344
51.2 Application in Myelin Disorders 347
51.3 Application in Isolated Myelin 348

Epilogue 351

References 353

Subject Index 386